ODI Pharma AB: Publication of interim report Q1 2022/2023
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report concerning the period July 2022 to September 2022. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.First quarter (2022-07-01 – 2022-09-30) The Group's net sales amounted to SEK 28,006 (0). The Group's loss after financial items amounted to SEK -1,598,205 (-1,175,388). Result per share amounted to SEK -0.11 (-0.08).* The solidity as of 2022-09-30 was 90% (94%).** * The Company’s result per share: The